Featured
Neurologists Discuss Cluster Headache Treatments
School Illness Sep 21, 2026
Lunch Nutrition Sep 19, 2026
Growth Charts Sep 18, 2026
Football players face a fourfold higher risk of developing ALS, according to a 2021 study,...
Australia's latest health literacy push, aged‑care shortages and heated tobacco policy debates in this week’s...
Free dental clinics in Victoria spark debate as Labor promises ten new sites, drawing praise...
Read our latest Germ Control articles.
Expert discusses TDP-43 role in ALS research, a protein present in 97% of ALS patients,...
Oveporexton shows symptom improvement in narcolepsy type 1, improving wakefulness and quality of life.
Coalition tobacco policy sparks health fears amid industry influence concerns, threatening public health.
Neurologists discuss cluster headache treatments and emerging approaches for chronic cluster headache patients.
Neurologists discuss cluster headache treatments and emerging approaches for chronic cluster headache patients.
New treatments emerge for Alzheimer's agitation, moving beyond off-label drug use with modest benefits.
Denali Therapeutics halted the SAR443820 trial after a phase 2 study failed to slow functional decline in adults with ALS,...
Genetic testing aids epilepsy diagnosis in children with seizures and developmental delays, offering new insights into disease origins.
Expert discusses TDP-43 role in ALS research, a protein present in 97% of ALS patients, to make ALS livable.
Oveporexton shows symptom improvement in narcolepsy type 1, improving wakefulness and quality of life.
Eight new muscular dystrophy therapies show promise in targeting disease mechanisms, moving beyond traditional care to advanced treatments for neuromuscular...
Football players face a fourfold higher risk of developing ALS, according to a 2021 study, sparking concern over long-term neurological...
The FDA fast-tracks satralizumab for MOGAD, a rare autoimmune disease. This decision could make it the first approved therapy for...
Gene therapy shows promise for seizure patients with sustained reductions in seizure frequency and improved behavior.